摘要
套细胞淋巴瘤(mantle cell lymphoma,MCL)属于B细胞源性侵袭性非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL),具有特征性染色体易位t(11;14),可导致细胞周期蛋白D1过表达,临床特征表现为病变广泛播散,10%~15%的患者呈现惰性、慢性病程。MCL好发于中老年男性,占成人NHL的6%~8%,中位生存期为3~5年。本文对近年来MCL的诊断和治疗做一综述,供临床参考。
Mantle cell lymphoma(MCL),being a kind of B cell aggressive non-Hodgkin's lymphoma(NHL),has a characteristic chromosomal translocation t(11;14),which leads to the overexpression of cyclin D1.The clinical manifestations are characterized by the widespread of the disease,and 10%~15%of the patients present with an inert and chronic course of disease,accounts for 6%~8%of NHL in adults,which is common in middle-aged and elderly men,and this disease's median survival is 3~5 years.This article reviews the diagnosis and treatment of MCL in recent years for clinical reference.
作者
郭莉
杨顺娥
Guo Li;Yang Shun'e(Department of Lymphoma Division,Cancer Hospital Affiliated to Xinjiang Medical University,Urumqi 830000,China)
出处
《肿瘤综合治疗电子杂志》
2020年第2期36-41,共6页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家自然科学基金项目(81660035)
新疆医科大学科研创新基金(XJC201150)。
关键词
套细胞淋巴瘤
诊断
治疗
Mantle cell lymphoma
Diagnosis
Treatment
